461 related articles for article (PubMed ID: 30128829)
1. Molecular Subtypes of Bladder Cancer.
McConkey DJ; Choi W
Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
[TBL] [Abstract][Full Text] [Related]
2. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
4. Genomic Subtyping in Bladder Cancer.
Jalanko T; de Jong JJ; Gibb EA; Seiler R; Black PC
Curr Urol Rep; 2020 Mar; 21(2):9. PubMed ID: 32166460
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer genomics.
Siracusano S; Rizzetto R; Porcaro AB
Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
[TBL] [Abstract][Full Text] [Related]
9. Contemporary Molecular Classification of Urinary Bladder Cancer.
Goutas D; Tzortzis A; Gakiopoulou H; Vlachodimitropoulos D; Giannopoulou I; Lazaris AC
In Vivo; 2021; 35(1):75-80. PubMed ID: 33402452
[TBL] [Abstract][Full Text] [Related]
10. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
Warrick JI; Sjödahl G; Kaag M; Raman JD; Merrill S; Shuman L; Chen G; Walter V; DeGraff DJ
Eur Urol; 2019 Jan; 75(1):18-22. PubMed ID: 30266310
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
13. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
Warrick JI; Al-Ahmadie H; Berman DM; Black PC; Flaig TW; Höglund M; Bubendorf L; van der Kwast TH; Cheng L;
Am J Surg Pathol; 2024 Jan; 48(1):e32-e42. PubMed ID: 37199442
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.
Li Y; Yang K; Li K; Liu H; Zhao S; Jiao M; Fu X
J Cell Biochem; 2019 Jun; 120(6):9956-9963. PubMed ID: 30548659
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
17. Genetic subtypes of invasive bladder cancer.
McConkey DJ; Choi W; Dinney CP
Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
[TBL] [Abstract][Full Text] [Related]
18. Molecular Biology of Bladder Cancer: Potential Implications for Therapy.
McConkey DJ
Hematol Oncol Clin North Am; 2021 Jun; 35(3):457-468. PubMed ID: 33958145
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Luminal and Basal Phenotypes in Bladder Cancer.
Guo CC; Bondaruk J; Yao H; Wang Z; Zhang L; Lee S; Lee JG; Cogdell D; Zhang M; Yang G; Dadhania V; Choi W; Wei P; Gao J; Theodorescu D; Logothetis C; Dinney C; Kimmel M; Weinstein JN; McConkey DJ; Czerniak B
Sci Rep; 2020 Jun; 10(1):9743. PubMed ID: 32546765
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of molecular subtyping in bladder cancer.
Satyal U; Sikder RK; McConkey D; Plimack ER; Abbosh PH
Curr Opin Urol; 2019 Jul; 29(4):350-356. PubMed ID: 31158107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
